Description
ADSB-FUB-187
ADSB-FUB-187 It’s cannabinoid and analog of ADB-Fubinaca IUPAC name: 7-chloro-N-[(2S)-1-[2-(cyclopropylsulfonylamino)ethylamino]-3,3-dimethyl-1-oxobutan-2-yl]-1-[(4-fluorophenyl)methyl]indazole-3-carboxamide CAS number: 1185283-97-9
Formula: C26H31ClFN5O4S
Purity: 99,8% min
Appearance: white powder/yellow powder.
ADSB-FUB-187 is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of Ki = 0.09 nM and an EC50 of 1.09 nM. It was originally developed by Pfizer in 2009, being example 187 from patent WO 2009/106982. While it is the most tightly binding compound from this patent in terms of Ki, it is not the most potent compound at producing a CB1 mediated pharmacological effect, with at least 17 other compounds from the patent having lower EC50 values
The physiological and toxicological properties of this compound are not known. This product is intended for forensic and research applications.
Shults –